This inventor holds 33 USPTO granted patents and 12 published patent applications, plus 6 CIPO patents and 16 EPO patents, primarily in Protein Engineering. Top assignees: X-Body, Inc., X-Chem, Inc., Compound Therapeutics, Inc.. Active years: 2002-2023.
Location History:
- Concord, MA (US) (2002 - 2017)
- Cambridge, MA (US) (2011 - 2023)
Company Filing History:
12 out of 31 
5 out of 6 
4 out of 6 
Years Active: 2002-2023
Areas of Expertise:
Title: Richard W. Wagner: Innovator in Antigen-Binding Polypeptides
Introduction
Richard W. Wagner is a prominent inventor based in Cambridge, MA, with a remarkable portfolio comprising 23 patents. His contributions to the field of biochemistry, particularly in the development of innovative antigen-binding polypeptides, have significant implications for therapeutic applications, including cancer treatment.
Latest Patents
One of Wagner's latest patents focuses on bi-specific antigen-binding polypeptides. This invention presents antigen-binding polypeptides that demonstrate high affinity for two target antigens simultaneously. Notably, the patent describes novel polypeptides that specifically bind to HER2 and inhibit HER2 activation, showcasing potential in cancer therapies. Furthermore, this patent includes nucleic acids encoding these polypeptides, recombinant expression vectors, and host cells designed for producing them. Another key patent pertains to antibody screening methods, which introduce new techniques for generating antibodies with improved binding specificity and stability compared to reference antibodies. These innovations enhance the overall effectiveness of therapeutic antibodies.
Career Highlights
Wagner has worked with notable companies, including X-Body, Inc. and X-Chem, Inc., where he has applied his expertise in developing cutting-edge biopharmaceuticals. His extensive research and development efforts have propelled advancements in the field, particularly regarding the design and functionality of therapeutic antibodies and antigen-binding polypeptides.
Collaborations
Throughout his career, Wagner has collaborated with several talented individuals, including Yan Chen and Matthew Clark. These partnerships have enhanced his research capabilities and fostered innovation within the biopharmaceutical domain, leading to valuable discoveries and breakthroughs.
Conclusion
Richard W. Wagner's expertise and contributions to the field of antigen-binding polypeptides position him as a leading inventor in biomedical innovation. With a strong focus on developing therapies for cancer and other diseases, his work continues to influence the landscape of biochemistry and therapeutic treatment options, demonstrating the critical role of inventors in advancing medical science.